Phase 3 Readout~month

Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati

Indication
Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma

Other upcoming events for IMNN

Patent ExpiryPatent/Exclusivity Expiry: AKEEGA
Patent ExpiryPatent/Exclusivity Expiry: ZEJULA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati — IMNN Phase 3 Readout | BioSniper